{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:13:45Z","timestamp":1778926425683,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["CKTO 2004-04"],"award-info":[{"award-number":["CKTO 2004-04"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.breast.2026.104749","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:35:08Z","timestamp":1773419708000},"page":"104749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02)"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-6386","authenticated-orcid":false,"given":"Mark","family":"Opdam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2101-4459","authenticated-orcid":false,"given":"Nigel","family":"Ultee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill J.J.","family":"Geenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7495-4786","authenticated-orcid":false,"given":"Annelot G.J.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid A.M.","family":"Mandjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1205-1895","authenticated-orcid":false,"given":"Sara","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-2721","authenticated-orcid":false,"given":"Renee X.","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrika M.","family":"Oosterkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5541-0347","authenticated-orcid":false,"given":"Sabine C.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104749_bib1","unstructured":"Organization WH. Breast cancer. Updated 13-04-2024. Accessed 2-July-2024, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"issue":"3","key":"10.1016\/j.breast.2026.104749_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3747\/co.v16i3.377","article-title":"Optimal use of taxanes in metastatic breast cancer","volume":"16","author":"King","year":"2009","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrclinonc.2009.186","article-title":"Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer","volume":"7","author":"Bedard","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104749_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrclinonc.2010.122","article-title":"Rechallenging with anthracyclines and taxanes in metastatic breast cancer","volume":"7","author":"Palmieri","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2026.104749_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100\u2008000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.breast.2026.104749_bib6","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104749_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jnci\/djn089","article-title":"Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"10384","key":"10.1016\/j.breast.2026.104749_bib8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.breast.2026.104749_bib9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ctrv.2012.02.011","article-title":"Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies","volume":"38","author":"Murray","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"10.1016\/j.breast.2026.104749_bib10","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jnci\/djq306","article-title":"Cancer biomarkers: can we turn recent failures into success?","volume":"102","author":"Diamandis","year":"2010","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104749_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2018.07.013","article-title":"Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: first results of the randomised MATADOR trial (BOOG 2004-04)","volume":"102","author":"van Rossum","year":"2018","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.breast.2026.104749_bib12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1349-7006.2006.00265.x","article-title":"Predictive factors for response to docetaxel in human breast cancers","volume":"97","author":"Noguchi","year":"2006","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.breast.2026.104749_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-011-1715-8","article-title":"Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy","volume":"130","author":"Loibl","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2026.104749_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10549-010-0761-y","article-title":"Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers","volume":"124","author":"Castellano","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.breast.2026.104749_bib15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41416-019-0630-3","article-title":"Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial","volume":"121","author":"Witzel","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104749_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2407-7-63","article-title":"Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy","volume":"7","author":"Lee","year":"2007","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104749_bib17","first-page":"189","article-title":"Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer","volume":"1","author":"Gasparini","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.breast.2026.104749_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/PL00008478","article-title":"Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy","volume":"126","author":"Mottolese","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.breast.2026.104749_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-8-153","article-title":"Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer","volume":"8","author":"Callagy","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104749_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.anndiagpath.2018.02.005","article-title":"Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy","volume":"35","author":"Abdelrahman","year":"2018","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib21","first-page":"142","article-title":"Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers","volume":"8","author":"Li","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.breast.2026.104749_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13000-016-0491-5","article-title":"EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features","volume":"11","author":"Guo","year":"2016","journal-title":"Diagn Pathol"},{"issue":"14","key":"10.1016\/j.breast.2026.104749_bib23","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1158\/1078-0432.CCR-18-4024","article-title":"EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy","volume":"25","author":"Puppe","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2026.104749_bib24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ejso.2007.07.008","article-title":"Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers","volume":"34","author":"Arai","year":"2008","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.radonc.2011.07.009","article-title":"Constitutive expression of \u03b3-H2AX has prognostic relevance in triple negative breast cancer","volume":"101","author":"Nagelkerke","year":"2011","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104749_bib26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.12.6.15956","article-title":"The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells","volume":"12","author":"Wilson","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4048\/jbc.2015.18.1.16","article-title":"Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer","volume":"18","author":"Kim","year":"2015","journal-title":"J Breast Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104749_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-005-9020-z","article-title":"Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers","volume":"94","author":"Tham","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.breast.2026.104749_bib29","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.ejca.2004.03.014","article-title":"Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy","volume":"40","author":"Vincent-Salomon","year":"2004","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-011-1427-0","article-title":"Prognostic utility of \u03b2-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic cooperative oncology group (HeCOG) study","volume":"127","author":"Pentheroudakis","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2026.104749_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3816\/CBC.2000.n.020","article-title":"A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923","volume":"1","author":"Hamilton","year":"2000","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0196-72","article-title":"Loss of normal p53 function confers sensitization to taxol by increasing G2\/M arrest and apoptosis","volume":"2","author":"Wahl","year":"1996","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ijc.10575","article-title":"Mutational analysis of the class I beta-tubulin gene in human breast cancer","volume":"101","author":"Hasegawa","year":"2002","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104749_bib34","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ijc.22557","article-title":"Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins","volume":"120","author":"Tommasi","year":"2007","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.breast.2026.104749_bib35","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-07-4741","article-title":"Class III \u03b2-Tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel","volume":"14","author":"Galmarini","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2026.104749_bib36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1634\/theoncologist.2013-0075","article-title":"Neoadjuvant doxorubicin\/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of \u03b2III-tubulin expression as a predictive marker","volume":"18","author":"Saura","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104749_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110425","article-title":"Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial","author":"Opdam","year":"2024","journal-title":"iScience"},{"issue":"69","key":"10.1016\/j.breast.2026.104749_bib38","doi-asserted-by":"crossref","first-page":"113531","DOI":"10.18632\/oncotarget.22697","article-title":"Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy","volume":"8","author":"van Rossum","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2026.104749_bib40","article-title":"MATADOR: a prospective, randomised, phase III biomarker trial in breast cancer patients","volume":"2","author":"Opdam","year":"2024","journal-title":"Mendeley Data"},{"issue":"8","key":"10.1016\/j.breast.2026.104749_bib41","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2026.104749_bib42","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.ccell.2023.05.009","article-title":"Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity","volume":"41","author":"Vennin","year":"2023","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.breast.2026.104749_bib43","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-1016-03","article-title":"Cellular immunity in breast cancer patients completing taxane treatment","volume":"10","author":"Carson","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104749_bib44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-011-1591-2","article-title":"Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression","volume":"132","author":"Alford","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.breast.2026.104749_bib45","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/annonc\/mdu391","article-title":"High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer","volume":"25","author":"Reijm","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"7577","key":"10.1016\/j.breast.2026.104749_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.breast.2026.104749_bib48","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1158\/2326-6066.CIR-19-0616","article-title":"Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4\/IKK2\/SNARE-Dependent exocytosis","volume":"8","author":"Lau","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104749_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188607","article-title":"\u03b2III-tubulin overexpression in cancer: causes, consequences, and potential therapies","volume":"1876","author":"Kanakkanthara","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104749_bib50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.breast.2026.104749_bib51","doi-asserted-by":"crossref","first-page":"iv14","DOI":"10.1093\/annonc\/mdi902","article-title":"Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer","volume":"16","author":"Paradiso","year":"2005","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104749_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clbc.2012.11.003","article-title":"High expression of class III \u03b2-Tubulin predicts good response to neoadjuvant taxane and Doxorubicin\/cyclophosphamide-based chemotherapy in estrogen receptor\u2013negative breast cancer","volume":"13","author":"Wang","year":"2013","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104749_bib53","first-page":"33","article-title":"Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology","volume":"7","author":"Simon","year":"2010","journal-title":"M\u00e9d Sur"},{"issue":"3","key":"10.1016\/j.breast.2026.104749_bib54","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the dependency of cellular protein levels on mRNA abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.breast.2026.104749_bib55","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1091\/mbc.10.4.947","article-title":"Taxol suppresses dynamics of individual microtubules in living human tumor cells","volume":"10","author":"Yvon","year":"1999","journal-title":"Mol Biol Cell"},{"issue":"13","key":"10.1016\/j.breast.2026.104749_bib56","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jnci\/89.13.917","article-title":"Multidrug resistance in breast cancer: a meta-analysis of MDR1\/gp170 expression and its possible functional significance","volume":"89","author":"Trock","year":"1997","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.breast.2026.104749_bib57","first-page":"389","article-title":"Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin","volume":"4","author":"Mechetner","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2026.104749_bib58","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/labinvest.2008.11","article-title":"Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays","volume":"88","author":"Ravo","year":"2008","journal-title":"Lab Invest"},{"issue":"8","key":"10.1016\/j.breast.2026.104749_bib59","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:59:19Z","timestamp":1778925559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":58,"alternative-id":["S0960977626000597"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104749","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02)","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104749"}}